Galderma Group AG (SWX: GALD)

Market Cap	19.20B
Revenue (ttm)	3.88B
Net Income (ttm)	-12.76M
Shares Out	237.92M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	39.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,667,194
Open	76.60
Previous Close	80.70
Day's Range	76.60 - 77.73
52-Week Range	53.00 - 84.92
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 3, 2024

About Galderma Group AG

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 6,545
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: GALD

Financial Performance

In 2023, GALD's revenue was $4.12 billion, an increase of 7.65% compared to the previous year's $3.82 billion. Losses were -$57.20 million, -41.93% less than in 2022.

Financial numbers in USD